Kenneth J Mc Grath Net Worth

The estimated Net Worth of Kenneth J Mc Grath is at least $1.21 millió dollars as of 30 May 2023. Kenneth Grath owns over 100,000 units of Orasure Technologies stock worth over $1,213,426 and over the last 2 years Kenneth sold OSUR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kenneth Grath OSUR stock SEC Form 4 insiders trading

Kenneth has made over 1 trades of the Orasure Technologies stock since 2023, according to the Form 4 filled with the SEC. Most recently Kenneth bought 100,000 units of OSUR stock worth $493,000 on 30 May 2023.

The largest trade Kenneth's ever made was buying 100,000 units of Orasure Technologies stock on 30 May 2023 worth over $493,000. On average, Kenneth trades about 16,667 units every 0 days since 2022. As of 30 May 2023 Kenneth still owns at least 285,512 units of Orasure Technologies stock.

You can see the complete history of Kenneth Grath stock trades at the bottom of the page.

What's Kenneth Grath's mailing address?

Kenneth's mailing address filed with the SEC is C/O ORASURE TECHNOLOGIES, INC., 220 EAST FIRST STREET, BETHLEHEM, PA, 18015.

Insiders trading at Orasure Technologies

Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair és Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.

What does Orasure Technologies do?

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo

Complete history of Kenneth Grath stock trades at Orasure Technologies

Orasure Technologies executives and stock owners

Orasure Technologies executives and other stock owners filed with the SEC include:

• Stephen Tang,
  President, Chief Executive Officer, Director
• Dr. Stephen S. Tang,
  Pres, CEO & Director
• Roberto Cuca,
  Chief Financial Officer
• Kathleen Gallagher Weber,
  Exec. VP & Bus. Unit Leader of Molecular Solutions
• Jack Jerrett,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kathleen Weber,
  Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG
• Scott Gleason,
  Sr. VP of Investor Relations & Corp. Communications and Interim CFO
• Michael Celano,
  Independent Chairman of the Board
• Ronny Lancaster,
  Independent Director
• Eamonn Hobbs,
  Independent Director
• Mara Aspinall,
  Independent Director
• James Datin,
  Independent Director
• David Shulkin,
  Independent Director
• Lelio Marmora,
  Director
• Michele Miller,
  Vice President - Finance, Controller, Assistant Secretary
• Lisa Nibauer,
  Executive Vice President, Business Unit Leader, Infectious Disease
• Amy Steigerwalt,
  VP of HR
• David A. Rappaport C.F.A., CFA,
  Sr. VP Corp. Devel., Strategy & Integration
• Carrie Eglinton Manner,
  Pres, CEO & Director
• Michele Marie Miller,
  VP of Fin., Controller & Assistant Sec.
• Agnieszka M. Gallagher J.D.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Lisa Nibauer,
  Pres of Diagnostics
• Jeanne Mell,
  VP of Corp. Communications
• Michele Marie Anthony,
  SVP Finance & CAO
• Douglas G Watson,
  Director
• Mark L Kuna,
  VP & Controller
• Roger L Pringle,
  Director
• Michael Reed,
  SVP R&D and CSO
• Ronald H Spair,
  Exec. VP & CFO
• Douglas A Michels,
  President and CEO
• Brian Smith,
  EVP & BU Lead - Molecular
• Nancy J Gagliano,
  Director
• Gregory B Lawless,
  Director
• Aradhana Sarin,
  Director
• Gerald M Ostrov,
  Director
• Eric Whitters,
  SVP, Research and Development
• Stephen R Lee,
  EVP & Chief Science Officer
• P Michael Formica,
  Exec. VP - Operations
• Michael J Gausling,
  President & CEO
• Joseph E Zack,
  Exec. VP, Marketing & Sales
• Manuel O. Mendez,
  VP, Marketing and Sales
• Frank G Hausmann,
  Director
• Jack Goldstein,
  Director
• Carter H Eckert,
  Director
• Ii Anthony Zezzo,
  EVP & BU Lead - Infectious
• Charles W Patrick,
  Director
• John P. Kenny,
  Director
• Robert W. Mc Mahon,
  Director
• Agnieszka Gallagher,
  General Counsel & CCO
• Scott Gleason,
  Interim CFO/SVP IR
• Anne Clem Whitaker,
  Director
• Manner Carrie Eglinton,
  President & CEO
• Kenneth J Mc Grath,
  Chief Financial Officer